Dr. Richard M. Schwartz, Ph.D., is currently the Chief of the Vaccine Production Program (VPP) at the Vaccine Research Center (VRC) at the NIAID/NIH. Dr. Schwartz has over 25 years experience in pharma and biotech while working in diverse areas including pharmaceutical natural product production, hematopoetic stem cells and vaccines. In his current position, he leads an organization responsible for the development and manufacturing of new VRC vaccine candidates for HIV, influenza, filoviruses and other emerging diseases. Additionally, he manages the business and manufacturing of the VRC products in a VRC funded, contractor operated fully integrated 126,000 ft2 pilot plant.
Dr. Schwartz was previously the Senior Director of Process and Manufacturing Sciences at MedImmune Vaccines where he was responsible for vaccine development and clinical manufacturing of new vaccine candidates as well as for providing manufacturing support to commercial vaccine manufacturing operations. Additionally, he was team leader for a BARDA funded development effort to convert FluMist from egg-based to a cell culture based production process. Prior to MedImmune, Dr. Schwartz worked at SyStemix, Aastrom Biosciences, and Eli Lilly. Dr. Schwartz received his B.S, M.S. and Ph.D. in Chemical Engineering from the University of Michigan.